Pfizer drug fails to beat tamoxifen at 2.75 years

[News]

Pfizer Inc said on Thursday its Aromasin cancer drug was no betterthan tamoxifen at achieving disease-free survival after 2.75 yearsamong postmenopausal women with hormone-sensitive early breastcancer.

More... (http://www.healthcentral.com/breast-cancer/news-278219-66.html)